Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma

Highlights • BSc2118 causes cell cycle arrest and induces apoptosis through p53 and caspase pathways in multiple myeloma. • BSc2118 inhibits multiple myeloma proliferation and angiogenesis in vitro and in vivo. • BSc2118 could partially overcome acquired bortezomib resistance in vitro , likely throu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2015-10, Vol.366 (2), p.173-181
Hauptverfasser:	Zang, Meirong, Li, Zengjun, Liu, Lanting, Li, Fei, Li, Xin, Dai, Yun, Li, Wei, Kuckelkorn, Ulrike, Doeppner, Thorsten R, Hermann, Dirk M, Zhou, Wen, Qiu, Lugui, Jin, Fengyan
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Animals Anti-angiogenesis Antineoplastic Agents - therapeutic use Apoptosis Autophagy Bone marrow Boronic Acids - pharmacology Bortezomib Bortezomib resistance Butanes - therapeutic use Caspases - metabolism Cell cycle Cell Cycle - drug effects Cell growth Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Drug resistance Drug Resistance, Neoplasm Enzyme Activation Gene expression Hematology, Oncology and Palliative Medicine Humans Hypoxia Immunoglobulins Mice Mice, Inbred NOD Mice, SCID Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - metabolism Neovascularization, Pathologic - drug therapy NF-kappa B - metabolism Oligopeptides - therapeutic use Proteasome Endopeptidase Complex - metabolism Proteasome inhibitor Proteasome Inhibitors - therapeutic use Proteins Pyrazines - pharmacology Studies Tumor Suppressor Protein p53 - metabolism Up-Regulation Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!